AAAAAA

   
Results: 1-19 |
Results: 19
Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks
Authors: Alberts, SR Erlichman, C Sloan, J Okuno, SH Burch, PA Rubin, J Pitot, HC Goldberg, RM Adjei, AA Atherton, PJ Kaufmann, SH
Citation: Sr. Alberts et al., Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks, ANN ONCOL, 12(5), 2001, pp. 627-631
Birt-Hogg-Dube Syndrome: an autosomal dominant disorder with predisposition to cancers of the kidney, fibrofolliculomas, and focal cutaneous mucinosis
Authors: Lindor, NM Hand, J Burch, PA Gibson, LE
Citation: Nm. Lindor et al., Birt-Hogg-Dube Syndrome: an autosomal dominant disorder with predisposition to cancers of the kidney, fibrofolliculomas, and focal cutaneous mucinosis, INT J DERM, 40(10), 2001, pp. 653-656
A phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors
Authors: Ansell, SM Pitot, HC Burch, PA Kvols, LK Mahoney, MR Rubin, J
Citation: Sm. Ansell et al., A phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors, CANCER, 91(8), 2001, pp. 1543-1548
Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma
Authors: De Vreede, I Steers, JL Burch, PA Rosen, CB Gunderson, LL Haddock, MG Burgart, L Gores, GJ
Citation: I. De Vreede et al., Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma, LIVER TRANS, 6(3), 2000, pp. 309-316
Phase III evaluation of octreotide versus chemotherapy with 5-fluorouracilor 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer: A north central cancer treatment group study
Authors: Burch, PA Block, M Schroeder, G Kugler, JW Sargent, DJ Braich, TA Mailliard, JA Michalak, JC Hatfield, AK Wright, K Kuross, SA
Citation: Pa. Burch et al., Phase III evaluation of octreotide versus chemotherapy with 5-fluorouracilor 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer: A north central cancer treatment group study, CLIN CANC R, 6(9), 2000, pp. 3486-3492
Priming tissue-specific cellular immunity in a phase I trial of autologousdendritic cells for prostate cancer
Authors: Burch, PA Breen, JK Buckner, JC Gastineau, DA Kaur, JA Laus, RL Padley, DJ Peshwa, MV Pitot, HC Richardson, RL Smits, BJ Sopapan, P Strang, G Valone, FH Vuk-Pavlovic, S
Citation: Pa. Burch et al., Priming tissue-specific cellular immunity in a phase I trial of autologousdendritic cells for prostate cancer, CLIN CANC R, 6(6), 2000, pp. 2175-2182
Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride(CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy
Authors: Pitot, HC Goldberg, RM Reid, JM Sloan, JA Skaff, PA Erlichman, C Rubin, J Burch, PA Adjei, AA Alberts, SA Schaaf, LJ Elfring, G Miller, LL
Citation: Hc. Pitot et al., Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride(CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy, CLIN CANC R, 6(6), 2000, pp. 2236-2244
The Bajorin article reviewed
Authors: Burch, PA
Citation: Pa. Burch, The Bajorin article reviewed, ONCOLOGY-NY, 14(1), 2000, pp. 58-58
Results of irradiation or chemoirradiation following resection of gastric adenocarcinoma
Authors: Henning, GT Schild, SE Stafford, SL Donohue, JH Burch, PA Haddock, MG Trastek, VF Gunderson, LL
Citation: Gt. Henning et al., Results of irradiation or chemoirradiation following resection of gastric adenocarcinoma, INT J RAD O, 46(3), 2000, pp. 589-598
Results of irradiation or chemoirradiation for primary unresectable, locally recurrent, or grossly incomplete resection of gastric adenocarcinoma
Authors: Henning, GT Schild, SE Stafford, SL Donohue, JH Burch, PA Haddock, MG Gunderson, LL
Citation: Gt. Henning et al., Results of irradiation or chemoirradiation for primary unresectable, locally recurrent, or grossly incomplete resection of gastric adenocarcinoma, INT J RAD O, 46(1), 2000, pp. 109-118
Phase II evaluation of continuous-infusion 5-fluorouracil, leucovorin, mitomycin-C, and oral dipyridamole in advanced measurable pancreatic cancer - A North Central Cancer Treatment Group Trial
Authors: Burch, PA Ghosh, C Schroeder, G Allmer, C Woodhouse, CL Goldberg, RM Addo, F Bernath, AM Tschetter, LK Windschitl, HE Cobau, CD
Citation: Pa. Burch et al., Phase II evaluation of continuous-infusion 5-fluorouracil, leucovorin, mitomycin-C, and oral dipyridamole in advanced measurable pancreatic cancer - A North Central Cancer Treatment Group Trial, AM J CL ONC, 23(5), 2000, pp. 534-537
A North Central Cancer Treatment Group phase II trial of topotecan in relapsed gliomas
Authors: Burch, PA Bernath, AM Cascino, TL Scheithauer, BW Novotny, P Nair, S Buckner, JC Pfeifle, DM Kugler, JW Tschetter, LK
Citation: Pa. Burch et al., A North Central Cancer Treatment Group phase II trial of topotecan in relapsed gliomas, INV NEW DR, 18(3), 2000, pp. 275-280
Renal cell carcinoma metastatic to the pancreas: Clinical and radiologicalfeatures
Authors: Ghavamian, R Klein, KA Stephens, DH Welch, TJ LeRoy, AJ Richardson, RL Burch, PA Zincke, H
Citation: R. Ghavamian et al., Renal cell carcinoma metastatic to the pancreas: Clinical and radiologicalfeatures, MAYO CLIN P, 75(6), 2000, pp. 581-585
Phase II study of paclitaxel and cisplatin for advanced urothelial cancer
Authors: Burch, PA Richardson, RL Cha, SS Sargent, DJ Pitot, HC Kaur, JS Camoriano, JK
Citation: Pa. Burch et al., Phase II study of paclitaxel and cisplatin for advanced urothelial cancer, J UROL, 164(5), 2000, pp. 1538-1542
Prostate-specific antigen decline after withdrawal of low-dose megestrol acetate
Authors: Burch, PA Loprinzi, CL
Citation: Pa. Burch et Cl. Loprinzi, Prostate-specific antigen decline after withdrawal of low-dose megestrol acetate, J CL ONCOL, 17(3), 1999, pp. 1087-1088
North Central Cancer Treatment Group phase II study of 5-fluorouracil and high-dose levamisole for gastric and gastroesophageal cancer using survivalas the primary endpoint of efficacy
Authors: Burch, PA Keppen, MD Schroeder, G Rubin, J Krook, JE Dalton, RJ Gerstner, JB Jancewicz, MT Ebbert, LP
Citation: Pa. Burch et al., North Central Cancer Treatment Group phase II study of 5-fluorouracil and high-dose levamisole for gastric and gastroesophageal cancer using survivalas the primary endpoint of efficacy, AM J CL ONC, 22(5), 1999, pp. 505-508
Phase II North Central Cancer Treatment Group study of 2-chlorodeoxyadenosine in patients with recurrent glioma
Authors: Rajkumar, SV Burch, PA Nair, S Dinapoli, RP Scheithauer, B O'Fallon, JR Etzell, PS Leitch, JM Morton, RF Marks, RS
Citation: Sv. Rajkumar et al., Phase II North Central Cancer Treatment Group study of 2-chlorodeoxyadenosine in patients with recurrent glioma, AM J CL ONC, 22(2), 1999, pp. 168-171
Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer
Authors: Quella, SK Loprinzi, CL Sloan, J Novotny, P Perez, EA Burch, PA Antolak, SJ Pisansky, TM
Citation: Sk. Quella et al., Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer, J UROL, 162(1), 1999, pp. 98-102
Phase I study of 5-fluorouracil administered by protracted venous infusion, leucovorin, and pelvic radiation therapy
Authors: Martenson, JA Shanahan, TG O'Connell, MJ Cobau, CD Schroeder, G Burch, PA Levitt, R Rowland, KM
Citation: Ja. Martenson et al., Phase I study of 5-fluorouracil administered by protracted venous infusion, leucovorin, and pelvic radiation therapy, CANCER, 86(4), 1999, pp. 710-714
Risultati: 1-19 |